Terbinafine

特比萘芬

Report date: 2026/05/02 20:00:18
NME

Base Information

Drug NameTerbinafine
Drug Alias Nameterbinafinum特比萘酚terbinafina坦平那芬terbinafine +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSqualene monooxygenase inhibitors
TargetsSqualene monooxygenase
Therapy Area/IndicationsAxial SpondyloarthritisSpondylitis, AnkylosingProstatic Neoplasms +[7] 
Global Approved IndicationsTinea VersicolorTinea PedisTinea
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved DateN/A
Country/TerritoryUnited StatesSwitzerlandEU +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesOnyx AxiomSwiss Cancer InstituteNovartis Pharma Schweiz Ag
Inactive CompaniesOregon Health And Science UniversityMylan Pharmaceuticals Inc
Active IndicationsProstatic NeoplasmsMycoses
Inactive IndicationsAxial SpondyloarthritisSpondylitis, AnkylosingTinea Versicolor +[5] 

Other Information

ATC CodeD01AE15D01BA02
Related LinksWikipediaDrugBankKEGG